Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab for Cancer of Unknown Primary (SiARa-CUP)
NCT05024968Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2021
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in cancer of unknown primary (CUP), sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2021; status: completed.
02
Drugs
sintilimab
03
Conditions
cancer of unknown primary (CUP)
Beyond the preview
Go deeper on NCT05024968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05024968.